Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | British Journal of Haematology |
Vol/bind | 196 |
Udgave nummer | 2 |
Sider (fra-til) | 437-440 |
Antal sider | 4 |
ISSN | 0007-1048 |
DOI |
|
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
We thank all the patients and the participating centres for their contribution. We thank Gilead for contribution with research grant and supply of study drug idelalisib.
ID: 346779530